Evidence map›Paper›PMID 40502475›Full record

ReviewJournal of the Korean Society of Radiology2025

Attenuation Based Quantitative Evaluation of Hepatic Steatosis Using US: Current Status and Future Perspective.

Dong Ho Lee

Abstract readReview
In one paragraph

Review in Journal of the Korean Society of Radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Preface for the Special Issue on Liver Imaging in Focus].Journal of the Korean Society of Radiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatic steatosis is a key characteristic of metabolic dysfunction-associated steatotic liver disease and may progress to cirrhosis and end-stage liver disease through metabolic dysfunction-associated steatohepatitis in 10%-30% of patients. Consequently, early detection and accurate assessment are essential. Grayscale US has traditionally been used for evaluating hepatic steatosis; however, its limitations include reduced sensitivity for mild cases and subjective interpretation. In addition to controlled attenuation parameter, two-dimensional attenuation-based techniques have been recently introduced to quantify US beam attenuation for assessing hepatic steatosis, demonstrating high diagnostic accuracy and reproducibility while addressing some of the limitations of grayscale US. To enhance diagnostic precision and reduce measurement variability, the standardization of examination protocols, including measurement processes, is necessary. Additionally, further research is needed to explore the role of a multiparametric approach combining attenuation-based techniques with elastography in predicting disease progression. This review examines the principles, recent research findings, and future perspectives on attenuation-based quantitative evaluation of hepatic steatosis using US.

Indexed as

Fatty LiverMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Quantitative ImagingUltrasound

Identifiers

PMID40502475
PMCPMC12149873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.